Roche Diagnostics SARS-CoV-2 Rapid Antigen Test

An aid in identifying individuals infected by SARS-CoV-215


The SARS-CoV-2 Rapid Antigen Test is a reliable, rapid chromatopgraphic immunoassay for the qualitative detection of specific antigens of SARS-CoV-2 present in the human nasopharynx. 

This test is an aid in detecting antigen from the SARS-CoV-2 virus in individuals suspected of COVID-19. This product is strictly intended for professional use in laboratory and Point of Care environment. 

Test kit information


The kit is ready for use and contains all equipment needed to perform a test.


The following components are needed for a test and included in the kit:

  • Test device (individually in a foil pouch with desiccant)
  • Extraction buffer tube
  • Nozzle cap
  • Sterile swap
  • Film (can be attached to the test device when performing outdoor testing) 
  • Instructions for use
  • Quick Reference Guide


Contact Roche Diagnostics Belgium

Do you have any questions about Roche SARS-CoV-2 Rapid Antigen Test? Then contact us by using the form below.


You can ask for price offers by clicking here.

Other questions

For other generic questions, please use the button here below.

Testing the quick and easy way


Testing process for the SARS-CoV-2 Rapid Antigen Test15

Testing process

1. Collecting a sample (nasypharyngeal swab)


Insert a sterile swab into the patient's nostril, swab the surface of the posterior nasopharynx. Withdraw the swab from the nasal cavity.

Testing process

2a. Preparing a sample


Insert the swab into an extraction buffer tube. While squeezing the buffer tube, stir the swab more than 5 times.

Testing process

2b. Preparing a sample


Remove the swab while squeezing the sides of the tube to extract the liquid from the swab.

Testing process

2c. Preparing a sample


Press the nozzle cap tightly onto the tube. Continue with 3a. Performing a test.

Testing process

3a. Performing a test


Apply 3 drops of extracted sample to the specimen well of the test device.

Testing process

3b. Performing a test


Read the test result at 15 to 30 min.

Warning: Risk of incorrect results. Do not read the test result after 30 min.

Testing process

4. Interpreting results


A colored line appears in the top section of the result window to show that the test is working properly. This is the control line (C). Even if the control line is faint, the test should be considered to have been performed properly. If no control line is visible the test is invalid. 

In case of a positive result, a colored line appears in the lower section of the result window. This is the test line (T). Even if the test line is very faint or not uniform, the test result should be interpreted as a positive result.

Would you like to order Roche SARS-CoV-2 Rapid Antigen Test?
Ask for a price offer
Coronavirus close up

Roche’s response to the COVID-19 pandemic

Our commitment to help put a stop to the COVID-19 pandemic



  1. Su S, Wong G, Shi W, et al.-Trends Microbiol. 2016;24(6):490–502.-2016-Elecsys Anti-SARS-CoV-2 -L (v1.0)
  2. Zhu, N., Zhang, D., Wang, W. et al.-N Engl J Med 382(8) 727-733-2020-Elecsys Anti-SARS-CoV-2 -Lit (v1.0)
  3. Chan, J.F., Yuan, S., Kok, K.H., To, K.K., Chu, H., Yang, J. et al.-Lancet. 395, 514–523.-2020- El (v1.0)
  4. U.S. CDC. Published April 2, 2020. Accessed April 15, 2020. 
  5. WHO. Published March 29, 2020. Accessed April 15, 2020. 
  6. Kampf, G., Todt, D., Pfaender, S., Steinmann, E.-J Hosp Infect. 104(3), 246–251.-2020- Elecsys Ant (v1.0)
  7. Letko, M., Marzi, A., Munster, V. (2020).-Nat Microbiol. 1–8. doi:10.1038/s41564-020-0688-y.-2020- (v1.0)
  8. Hoffmann, M., Kleine-Weber, H., Schroeder, S. et al.-[published online ahead of print, 2020 Mar 4]. (v1.0)
  9. WHO. sitrep-74-covid-19-mp.pdf. Published April 3, 2020. Accessed April 15, 2020. 
  10. Lauer SA et al.-Ann Intern Med 2020;172(9):577-82-The Incubation Period of COVID-19 (v1.0)
  11. Rothe, C et al-N Engl J Med 2020;382(10):970-971-2020-Lab Infectious Diseases Respiratory tract infec (v1.0)
  12. Kupferschmidt K-Science. symptomatic-patienttrans (v1.0)
  13. Bai Y et al-JAMA 2020;323(14):1406-1407-2020-Lab Infectious Diseases Respiratory tract infections Co (v1.0)
  14. Mizumoto K et al-Euro Surveill 2020;25(10):2000180.-2020-Lab Infectious Diseases Respiratory tract i (v1.0)
  15. SARS-CoV-2 Rapid Antigen Test Package Insert 2020-09, V 1.0.